http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=13527
Genentech announced 24-month results from the two pivotal Phase III trials (RISE and RIDE) assessing the efficacy and safety of Lucentis® (ranibizumab injection) in people with diabetic macular edema (DME).
...patients who received Lucentis experienced significant, rapid and sustained improvement in vision compared to those who received placebo (sham) injections.
...patients who received Lucentis were significantly more likely to achieve 20/40 vision and experience less progression of the underlying diabetic retinopathy disease.
Genentech announced 24-month results from the two pivotal Phase III trials (RISE and RIDE) assessing the efficacy and safety of Lucentis® (ranibizumab injection) in people with diabetic macular edema (DME).
...patients who received Lucentis experienced significant, rapid and sustained improvement in vision compared to those who received placebo (sham) injections.
...patients who received Lucentis were significantly more likely to achieve 20/40 vision and experience less progression of the underlying diabetic retinopathy disease.
